Enanta Pharmaceuticals reported $-31824000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Amgen AMGN:US USD 3.5B 62M
Arrowhead Research ARWR:US USD -70306000 114.46M
AstraZeneca AZN:LN USD 3.6B 404M
Biogen BIIB:US USD 992.8M 82.9M
Bristol Myers Squibb BMY:US USD 5.32B 456M
Clovis Oncology CLVS:US USD -42347000 15.13M
Gilead Sciences GILD:US USD 3.28B 731M
GlaxoSmithKline GSK:LN GBP 3.36B 916M
Halozyme Therapeutics HALO:US USD 112.9M 66.29M
Insmed INSM:US USD -119864000 21.78M
Intercept Pharmaceuticals ICPT:US USD -10064000 808K
Johnson & Johnson JNJ:US USD 7.81B 876M
Karyopharm Therapeutics KPTI:US USD -30657000 12.1M
Marinus Pharmaceuticals MRNS:US USD -29941000 6.73M
Neurocrine Biosciences NBIX:US USD 91.8M 33.2M
Novartis NOVN:VX USD 4.69B 34M
Pfizer PFE:US USD 10.52B 2.78B
Ptc Therapeutics PTCT:US USD -33710000 29.47M
Sarepta Therapeutics SRPT:US USD -120652000 80.59M
Vertex Pharmaceuticals VRTX:US USD 1.16B 6.8M
Vital Therapies VTL:US USD -20099000 491K
YTE INCY:US USD 134.94M 141.85M